Cosmos Health Inc.
Close on Oct 19, 2026
- Market cap
- $19.48M
- P/E (TTM)
- –
- Dividend yield
- –
About Cosmos Health
Wholesale-Drugs, Proprietaries & Druggists' Sundries, SIC 5122
Cosmos Health Inc. is a vertically integrated healthcare company that develops, manufactures, and distributes generic pharmaceuticals, proprietary nutraceuticals, biocides, and other healthcare products. The company also operates a direct-to-consumer telehealth platform and conducts research and development focused on novel oncology therapies, weight management solutions, and AI-driven drug repurposing. Its offerings encompass prescription and over-the-counter medications, antiseptic soaps, and dietary supplements, as well as contract manufacturing organization services. The group's customer base includes retail pharmacies, wholesale drug distributors, hospitals, and clinics, along with individual consumers using its virtual care services.
The company's commercial activities are primarily concentrated in Europe, with Greece generating the vast majority of consolidated revenues alongside operations in the United Kingdom, other European countries, and the United Arab Emirates, with expansion into North America. Operations are supported by automated storage and distribution facilities utilizing robotic warehouse systems. The enterprise was originally incorporated in Nevada.
Summary of the business section of Cosmos Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cosmos Health Inc.
- Founded
- 2009
- Headquarters
- Thessaloniki, J3
- Address
- 5 Agiou Georgiou, Pilea 55438
- Phone
- (312) 536-3102
- Employees
- 163, Dec 31, 2025
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- RBSM LLP, New York, NY
Stock & identifiers
- Ticker
- COSM
- Exchange
- Nasdaq
- Shares outstanding
- 101M, Aug 18, 2026
- Public float
- $9.53M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Apr 12, 2023; 1-for-10 reverse, Apr 17, 2018; 1-for-10 reverse, Nov 21, 2017
- SEC CIK
- 1474167
- CUSIP
- 221413305
- ISIN
- US2214133058
- LEI
- 549300NN5KFIEHPECJ85
- EIN
- 27-0611758
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Grigorios Siokas | Chief Executive Officer, Director | 14,597,917 |
| Demetrios G. Demetriades | Secretary, Director | 55,000 |
| Georgios Terzis | Chief Financial Officer | 2,563,805 |
| Nikolaos Bardakis | Chief Operating Officer | 45,000 |
| Anastasios Aslidis | Director | 100,000 |
| Suhel Bhutawala | Director | 65,000 |
| John James Hoidas | Director | 50,000 |
| Theodoros Christos Karkantzos | Director | 35,000 |
| Manfred Ziegler | Director | 20,000 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 163 full-time employees.”
Corporate history
Events identified from SEC filings